New contamination-detection test to improve T-cell therapy
Method to improve sterility assurance in biopharmaceutic manufacturing will lead to better patient outcomes.
List view / Grid view
Method to improve sterility assurance in biopharmaceutic manufacturing will lead to better patient outcomes.
Haematology research is a cradle of innovation, with many firsts in therapeutic approaches utilising the latest technology for the treatment of blood cancers. Anas Younes, Senior Vice President, Head of Haematology Oncology Research and Development at AstraZeneca, envisions a future where potential cures are within reach for more blood cancers…
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
UW researchers at the Carbone Cancer Center have identified the cells that can cause graft versus host disease, the most common complication of bone marrow transplants.
Combining AI with cutting-edge flow cytometry and massive sequencing technologies, researchers describe CAR T cell characteristics that determine their therapeutic capacity for the first time.
A new study in mice has shown blood cancer treatment with protein interleukin-7 revs up T-cell immunotherapy.
Scientists have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumour cells.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Exposing umbilical cord blood to NOV proteins causes an increase in functional haematopoietic stem cells (HSCs) and could provide a more effective transplant option for blood cancer patients.
Researchers have provided new insight into the role of cyclic AMP (cAMP) in regulating the immune response which may lead to new ways of treating diseases.
Researchers have reprogrammed CAR T cells to prevent them becoming exhausted after prolonged activity, presenting a possible new therapy for solid tumours.